Article Data

  • Views 544
  • Dowloads 145

Original Research

Open Access

Is there a place for brachytherapy for patients with ovarian cancer?

  • M. Biedka1,2,*,
  • R. Makarewicz2

1Radiotherapy Department, Oncology Centre in Bydgoszcz, Bydgoszcz

2The Chair and Clinic of Oncology and Brachytherapy, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz (Poland)

DOI: 10.12892/ejgo4389.2019 Vol.40,Issue 3,June 2019 pp.373-379

Published: 10 June 2019

*Corresponding Author(s): M. Biedka E-mail: martabiedka@tlen.pl

Abstract

Ovarian cancer is currently the second cause of death among genitourinary tract neoplasms in developed countries. Surgical treatment combined with chemotherapy is the standard of treatment in ovarian cancer. Disease relapses, cases where standard therapeutic procedures proved unsuccessful and previous radiotherapy significantly limited the possibility of further radiological treatment, constitute the greatest oncological challenge. There are attempts at using radiotherapy and/or brachytherapy. The aim of this retrospective study was to assess the results of brachytherapy among ovarian cancer patients with disease relapse. The study included 24 ovarian cancer patients with disease relapse, treated with brachytherapy at the Department of Brachytherapy of the Oncology Centre in Bydgoszcz from January 2008 to December 2014. Patients in all stages of the disease were subject to analysis. Disease relapse was confirmed in 23 of 24 subjects, the lesion being present beyond the vaginal stump. Twenty-one patients reported symptoms, most often spotting or vaginal bleeding. A trend toward higher survival rate in a group of patients without changes in the vaginal stump (p = 0.07) was observed. It was demonstrated that presence of lesions in the stump was associated with more frequent progression and this result was statistically significant (p = 0.035). In the entire group of patients, spotting or vaginal bleeding subsided. In summary, brachytherapy may be a useful treatment modality in selected clinical situations involving ovarian cancer. This procedure is particularly useful for women with disease relapse, parametrum infiltration, and/or incomplete tumor resection.

Keywords

Brachytherapy; Ovarian cancer; Vaginal stump.

Cite and Share

M. Biedka,R. Makarewicz. Is there a place for brachytherapy for patients with ovarian cancer?. European Journal of Gynaecological Oncology. 2019. 40(3);373-379.

References

[1] Makarewicz R.: “Brachyterapia HDR”. Gdańsk: Via Medica, 2004.

[2] Glasgow G., Anderson L.: “High dose rate remote afterloading equipment W”. In: Nag S. (ed). High dose rate brachytherapy: a textbook”. Armonk, NY: Futura Publishing Co., 1994, 41.

[3] Yahara K., Ohguri T., Imada H., Yamaguchi S., Kawagoe T., Matsuura Y., et al.: “Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy”. J. Radiat. Res., 2013, 54, 322.

[4] Goldhirsch A., Greiner R., Dreher E., Sessa C., Krauer F., Forni M., et al.: “Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy”. Cancer, 1988, 62, 40.

[5] Heindl A., Lan C., Rodrigues D.N., Koelble K., Yuan Y.: “Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer”. Oncotarget, 2016, 7, 71123.

[6] Tukiendorf A., Wydmański J., Wolny-Rokicka E.: “Association between Stereotactic Radiotherapy and Death from Brain Metastases of Epithelial Ovarian Cancer: a Gliwice Data Re-Analysis with Penalization”. Asian Pac. J. Cancer Prev., 2017, 18, 1113.

[7] Yap S., Kapp D., Nelson N., Teng M., Husain A.: “Intraoperative radiation therapy in recurrent ovarian cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63, 1114.

[8] Larson D.M., Broste S.K., Krawisz B.R.: “Surgery without radiotherapy for primary treatment of endometrial cancer”. Obstet. Gynecol., 1998, 91, 355.

[9] Yoney A., Yildirim C., Bati Y., Unsal M.: “Low risk stage I endometrial carcinoma: rognostic factors and outcomes”. Indian J. Cancer, 2011, 48, 204.

[10] Ito H., Shigematsu N., Kawada T., Kubo A., Isobe K., Hara R., et al.: “Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy”. Gynecol. Oncol., 1997, 67, 154.

[11] Ito H., Kumagaya H., Shigematsu N., Nishiguchi I., Nakayama T., Hashimoto S.: “High dose rate intracavitary brachytherapy for recurrent cervical cancer of the vaginal stump following hysterectomy”. Int. J. Radiat. Oncol. Biol. Phys., 1991, 20, 927.

[12] Kasamatsu T., Onda T., Yamada T., Tsunematsu R.: “Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma”. Int. J. Gynecol. Obstet., 2005, 89, 39.

[13] Fujiwara K., Suzuki S., Yoden E., Ishikawa H., Imajo Y., Kohno I.: “Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemiotherapy”. Int. J. Gynecol. Cancer, 2002, 12, 250.

[14] Chassagne D., Dutreix A., Almond P., Burgers J.M.V., Busch M., Joslin C. A.: “Dose and Volume Specification for reporting Intracavitary Therapy in Gynecology”. ICRU Report 38. Journal of the International Commission on Radiation Units and Measurements, 1985, 20, .

[15] Randall M., Evans L., Greven K., Mc Cuniffin A., Doline R.: “Interstitial reirradiation for recurrent gynecologic malignancies: results and analysis of prognostic factors”. Gynecol. Oncol., 1993, 48, 23.

[16] Puthawala A.A., Syed A.M., Fleming P.A., DiSaia P.J.: “Re-irradiation with interstitial implant for recurrent pelvic malignancies”. Cancer, 1982, 50, 2810.

[17] Brabham J.G., Cardenes H.R.: “Permanent interstitial reirradiation with 198Au as salvage therapy for low volume recurrent gynecologic malignancies”. Am. J. Clin. Oncol., 2009, 32, 417.

[18] Guckenberger M., Bachmann J., Wulf J., Mueller G., Krieger T., Baier K., et al.: “Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynecological cancer”. Radiother. Oncol., 2010, 94, 53.

[19] Badakh D.K., Grover A.H.: “Reirradiation with high-dose-rate remote afterloading brachytherapy implant in patients with locally recurrent or residual cervical carcinoma”. J. Cancer Res. Ther., 2009, 5, 24.

[20] Okazawa K., Yuasa-Nakagawa K., Yoshimura R., Shibuya H.: “Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma”. J. Radiat. Res., 2013, 54, 299.

[21] Petignat P., Jolicoeur J., Alobaid A., Drouin P., Gauthier P., Provencher D.: “Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence”. Gynecol. Oncol., 2006, 101, 445.

[22] Ogino I., Kitamura T., Okamoto N., Nakayama H., Matsubara S.: “High dose rate intracavitary brachytherapy for recurrent or residual lesions in the vaginal cuff: results in post-hysterectomy patients with carcinoma of the cervix”. Int. J. Gynecol. Cancer, 2001, 11, 61.

[23] Gelblum D., Mychalczak B., Almadrones L., Spriggs D., Barakat R.: “Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma”. Gynecol. Oncol., 1998, 69, 36.

[24] Russell A.H., Koh W.J., Markette K., Russell K.J., Cain J.M., Tamimi H.K., et al.: “Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract”. Gynecol. Oncol., 1987, 27, 226.

[25] Krauss T., Meden H., Rath W., Kuhn W.: “Results of postoperative radiotherapy with iridium-192 in patients with ovarian cancer”. Zentralbl. Gynakol., 1992, 114, 603.

[26] Haasbeek C., Uitterhoeve A., Gonzalez J., Stalpers L.: “Long term results of salvage radiotherapy for treatement of recurrent cervical carcinoma after prior surgery” Radiother. Oncol., 2008, 89, 197.

[27] Hille A., Weiss E., Hess C.: “Therapeutic outcome and prognostic factors in the radiotherapy of recurrences of cervical carcinoma following surgery”. Strahlenther. Onkolo., 2003, 179, 742.

[28] Kishi K., Mabuchi Y., Sonomura T., Shirai S., Noda Y., Sato M., Ino K.: “Eradicative brachytherapy with hyaluronate gel injection into pararectal space in treatment of bulky vaginal stump recurrence of uterine cancer”. J. Radiat. Res., 2012, 53, 601.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top